Prescient Therapeutics: Investor Briefing with CEO James McDonnell
CEO James McDonnell, held a shareholder briefing with Reach Markets.
In this session, James discussed:
- Our outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.
- The designations received from the FDA which could allow Prescient to head toward a US$1.8bn market after Phase 2.
- Why our technology could apply to 22% of all cancer 22% of all cancer cases (Lung, Pancreas, Ovarian etc.)
Recorded on 16th July 2025 at 2pm (AEST)
Featured Speaker
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company’s acquistion by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
